Business Context and Reporting Period
Company: Adherex Technologies Inc. (Note: Metadata referenced "Fennec Pharmaceuticals," but the filing text identifies the registrant as Adherex Technologies Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Stage: Development-stage biopharmaceutical company focused on cancer therapeutics (eniluracil, ADH-1, and sodium thiosulfate/STS).
Going Concern Status: The filing explicitly states substantial doubt regarding the company's ability to continue as a going concern. Cash on hand is projected to fund operations only into the first quarter of 2010. The company has not been successful in obtaining additional financing since February 2007.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Dec 31, 2008 (Balance Sheet) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(35,000) | $(3,219,000) | N/A |
| Operating Expenses | $(340,000) | $(3,253,000) | N/A |
| Cash and Cash Equivalents | $868,000 | N/A | $5,349,000 |
| Working Capital | $590,000 | N/A | $3,209,000 |
| Accumulated Deficit | $(101,198,000) | N/A | $(97,979,000) |
| Stockholders' Equity | $376,000 | N/A | $3,053,000 |
Note: All figures in thousands of U.S. dollars unless otherwise noted.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased significantly compared to the prior year periods. For the nine months ended September 30, 2009, expenses were $3.25 million compared to $11.25 million in the same period in 2008. This is primarily due to a 75% reduction in employee headcount effective April 2009 and the termination of the topical eniluracil study.
- Cash Burn: Cash and cash equivalents declined from $5.35 million at year-end 2008 to $0.87 million at September 30, 2009. Net cash used in operating activities for the nine-month period was $4.5 million.
- Asset Impairments: The company recorded a $386,000 loss on impairment of assets held for sale and leasehold inducements for the nine months ended September 30, 2009, as the fair value of these assets was determined to be nil.
- Other Income: Other income increased due to a $323,000 gain on the termination of deferred rent associated with the Maplewood lease termination.
Outlook, Risks, and Management Commentary
- Strategic Pivot: Management announced a focus on the development of oral eniluracil combined with 5-FU. The topical eniluracil study was terminated. The company plans to design a Phase II study within 3-9 months, contingent on securing adequate funding.
- Liquidity Crisis: Management states that current cash resources will only sustain operations into the first quarter of 2010. If a strategic transaction or additional financing is not secured in the "very near term," the company may cease operations sooner.
- Management Turnover: Significant leadership changes occurred in Q3 2009, including the departure of the CEO, CFO, and several directors. New leadership was appointed in July and September 2009.
- Delisting: The company's common stock was delisted from the NYSE Alternext US (AMEX) in January 2009 and now trades on the over-the-counter (pink sheets) market. There is a risk of delisting from the Toronto Stock Exchange (TSX) if listing requirements are not met.
- Risk Factors: Key risks include the inability to raise capital, failure of clinical trials, dependence on third-party collaborators (GSK, McGill, OHSU), and potential termination of license agreements due to non-payment.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "first quarter of 2010" cash runway projection given the volatility of the biotech financing market.
- Financing Plans: Confirm if any definitive agreements for equity financing, debt, or strategic collaborations have been signed since the filing date (November 13, 2009).
- License Status: Review the status of critical licenses with GSK (eniluracil), McGill (ADH-1), and OHSU (STS) to ensure no termination notices have been issued due to missed payments.
- Management Stability: Assess the integration and retention of the new executive team appointed in mid-2009.
- Stock Liquidity: Evaluate the trading volume and liquidity of the stock on the OTC market and TSX, noting the risks associated with penny stock rules and potential further delisting.